TuisONC • TSE
add
Oncolytics Biotech Inc
Vorige sluiting
$0,81
Dagwisseling
$0,76 - $0,80
Jaarwisseling
$0,67 - $2,08
Markkapitalisasie
61,62 m CAD
Gemiddelde volume
56,13 k
P/V-verhouding
-
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CAD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 8,44 m | -4,66% |
Netto inkomste | -8,02 m | -103,01% |
Netto winsgrens | — | — |
Wins per aandeel | -0,10 | 9,91% |
EBITDA | -8,43 m | 4,56% |
Effektiewe belastingkoers | -0,29% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CAD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 15,94 m | -54,34% |
Totale bates | 20,19 m | -48,00% |
Totale aanspreeklikheid | 14,20 m | 26,18% |
Totale ekwiteit | 5,98 m | — |
Uitstaande aandele | 86,42 m | — |
Prys om te bespreek | 11,57 | — |
Opbrengs op bates | -94,91% | — |
Opbrengs op kapitaal | -245,72% | — |
Kontantvloei
Netto kontantverandering
| (CAD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -8,02 m | -103,01% |
Kontant van bedrywe | -7,85 m | -28,12% |
Kontant van beleggings | -6,00 k | -100,00% |
Kontant van finansiering | 3,34 m | 91,68% |
Netto kontantverandering | -3,66 m | 27,88% |
Beskikbare kontantvloei | -4,62 m | 44,28% |
Meer oor
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Gestig
1998
Hoofkwartier
Webwerf
Werknemers
28
